November 02, 2020
Zetia (Ezetimibe) Antitrust v. Merck & Company, Inc.
Nature of Suit:
Sectors & Industries:
View recent docket activity
Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.
August 04, 2021
Zetia Judge Must Rethink 'Faulty' Class Cert., 4th Circ. Says
A Fourth Circuit panel hit the reset button Wednesday on the certification of a class of 35 drug wholesalers suing Merck and Glenmark for allegedly delaying generic entry of Merck cholesterol drug Zetia, remanding the antitrust case so a Virginia federal judge can reconsider her "faulty logic."
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
- Direct access to case information and documents.
- All significant new filings across U.S. federal district courts, updated hourly on business days.
- Full-text searches on all patent complaints in federal courts.
- No-fee downloads of the complaints and so much more!
TRY LAW360 FREE FOR SEVEN DAYS
Already a subscriber? Click here to login